Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tolimidone (NSC 314335) 是选择性的 Lyn kinase 变构激活剂,其 EC50=63 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 172 | 现货 | ||
5 mg | ¥ 378 | 现货 | ||
10 mg | ¥ 628 | 现货 | ||
25 mg | ¥ 1,230 | 现货 | ||
50 mg | ¥ 1,830 | 现货 | ||
100 mg | ¥ 2,760 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 418 | 现货 |
产品描述 | Tolimidone (NSC 314335) is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals. |
靶点活性 | Lyn:63 nM(EC50) |
体外活性 | In an in vitro broad kinase screen MLR-1023 activated the nonreceptor-linked Src-related tyrosine kinase Lyn. MLR-1023 increased the Vmax of Lyn with an EC50 of 63 nM. This Lyn kinase activation was ATP binding site independent, indicating that MLR-1023 regulated the kinase through an allosteric mechanism[1]. |
体内活性 | MLR-1023-mediated blood glucose lowering depends on Lyn kinase activity[1]. MLR-1023 is an insulin receptor-potentiating agent that produces a rapid-onset and durable blood glucose-lowering activity in diabetic animals[2]. |
细胞实验 | Adipocyte differentiation is assessed in mouse 3T3-L1 cells after 8 days of incubation with MLR-1023 or rosiglitazone (10 μM).(Only for Reference) |
别名 | 托利咪酮, NSC 314335, MLR-1023, CP-26154 |
分子量 | 202.21 |
分子式 | C11H10N2O2 |
CAS No. | 41964-07-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.2 mg/mL (100 mM)
Ethanol: 4 mg/mL (20 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 4.9454 mL | 24.7268 mL | 49.4535 mL | 123.6338 mL |
5 mM | 0.9891 mL | 4.9454 mL | 9.8907 mL | 24.7268 mL | |
10 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL | 12.3634 mL | |
20 mM | 0.2473 mL | 1.2363 mL | 2.4727 mL | 6.1817 mL | |
DMSO | 50 mM | 0.0989 mL | 0.4945 mL | 0.9891 mL | 2.4727 mL |
100 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL | 1.2363 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tolimidone 41964-07-2 Angiogenesis Tyrosine Kinase/Adaptors Src NSC-314335 托利咪酮 NSC 314335 MLR-1023 Inhibitor CP-26154 CP 26154 MLR 1023 NSC314335 inhibit CP26154 MLR1023 inhibitor